SCHEMBL6317818

SCHEMBL6317818

CN(C(=O)c1ccc(Cl)cc1Cl)C(Cc1ccc(-c2cc3ccccc3o2)cc1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.44
MMP13 P45452 1/20 0.44
P2RY14 Q15391 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.40
ERAP1 Q9NZ08 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HPGD P15428 1/20 0.40
KDM4E B2RXH2 1/20 0.40
NFKB1 P19838 1/20 0.40
NPY1R P25929 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
FFAR1 O14842 1/20 0.39
BCHE P06276 4/20 0.39
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316090 0.88 MMP12 (0.43) MMP12MMP13ERAP1ALDH1A1HPGD
SCHEMBL6316097 0.88 MMP12 (0.43) MMP12MMP13ERAP1ALDH1A1HPGD
SCHEMBL6316102 0.86 ERAP1 (0.41) MMP12MMP13ADAMTS5ERAP1ALDH1A1
SCHEMBL6316107 0.86 ERAP1 (0.41) MMP12MMP13ADAMTS5ERAP1ALDH1A1
SCHEMBL6318724 0.86 MMP12 (0.41) MMP12MMP13P2RY14ERAP1NPC1
SCHEMBL6319773 0.86 MMP12 (0.41) MMP12MMP13P2RY14ERAP1NPC1
SCHEMBL6325127 0.83 TMEM97 (0.49) ADAMTS5NPC1RAB9ASMN1; SMN2
SCHEMBL6325131 0.83 TMEM97 (0.49) ADAMTS5NPC1RAB9ASMN1; SMN2
SCHEMBL6325062 0.81 MMP12 (0.44) MMP12MMP13P2RY14ADAMTS5ERAP1
SCHEMBL6325059 0.81 MMP12 (0.44) MMP12MMP13P2RY14ADAMTS5ERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US claimed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US claimed
US-6887877-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-05-03 US disclosed
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections SHIRE BIOCHEM INC. (CA) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229053-A1 Compounds and methods for the treatment or prevention of flavivirus infections HAVCR2, ZC3HAV1, MAVS MMP12 3249/4885MMP13 3690/4885P2RY14 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.